Merck's $1.05 Billion Trading Volume Ranks 103rd in U.S. Equities Amid Mixed Investor Sentiment

On September 23, 2025, Merck & Co. , ranking 103rd in trading volume among U.S. equities. , reflecting mixed investor sentiment amid evolving market dynamics.

Recent developments highlight Merck's strategic focus on its oncology pipeline, with regulatory updates on its experimental cancer therapy generating cautious optimism. Analysts noted that while short-term volatility persists, the company's long-term positioning in high-margin therapeutic areas remains intact. Institutional activity showed reduced short-term trading pressure compared to prior sessions, though no material insider transactions were reported.

Market participants are closely monitoring the pharmaceutical giant's upcoming earnings release, scheduled for late October. , with no significant changes in institutional ownership patterns observed in recent filings. Technical indicators suggest the stock remains within a consolidation phase, with key resistance levels near its 52-week high.

To set up this back-test correctly I need to pin down a couple of practical details: Market universe – do you want this applied to all U.S. listed common stocks (NYSE + NASDAQ + AMEX), or a pre-defined index constituent list (e.g., Russell 3000, S&P 1500), or another market? Re-balancing rule – the usual implementation for "buy top 500 by volume, hold 1 day" is: At today’s close rank all stocks by today’s dollar trading volume. Buy an equal-weighted basket of the top 500 at tomorrow’s open (or today’s close, please specify). Close (sell) at the next day’s close (i.e., 1-day holding period). Does that match your intended execution timing? Transaction costs – should I include an estimate (e.g., 2 bp per trade) or ignore costs? Weighting – equal weight each stock, or volume-weighted? Once I have these points, I’ll build the data-pull plan and run the back-test.